Gene-expression-based biomarker predicts long-term risk of breast cancer recurrence
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) - a biomarker based on the expression levels of seven tumor-specific genes - accurately identifies patients who continue to be at risk after five years of treatment with either tamoxifen or the aromatase inhibitor anastrozole. The study comparing the BCI with two other prognostic tests has been published online in Lancet Oncology... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 15, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Gene-expression-based biomarker predicts long-term risk of breast cancer recurrence
(Massachusetts General Hospital) A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor-positive breast cancer finds that only the breast cancer index -- a biomarker based on the expression levels of seven tumor-specific genes -- accurately identifies patients who continue to be at risk after five years of treatment with either tamoxifen or the aromatase inhibitor anastrozole. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2013 Category: Cancer & Oncology Source Type: news
Arimidex – Anastrozole – Aromatase...
Arimidex helps prevent the production of estrogen, a hormone that fuels many breast cancer tumors. It is considered a hormonal treatment, and can help prevent recurrence of breast cancer in postmenopausal women. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 28, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
What are Aromatase Inhibitors and How Do These...
Arimidex, Aromasin, and Femara are three aromatase inhibitors given as follow-up treatment after primary treatment for estrogen-receptor positive breast cancer. Aromatase inhibitors prevent the production of estrogen by inhibiting the enzyme aromatase. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 19, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Compare The Cost And Effectiveness of Tamoxifen...
Tamoxifen and Arimidex are two hormone therapy drugs that are important to prevent recurrence of hormone-sensitive breast cancer. Compare the cost and effectiveness of Tamoxifen and Arimidex, and get some tips on saving your money. Don't skip taking Tamoxifen or Arimidex if you had hormone-sensitive breast cancer. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 5, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Tamoxifen boost for breast cancer sufferers
Study finds that death rates fall significantly for patients who take the drug for 10 years rather than the standard fiveBreast cancer is less likely to recur if women previously treated for the disease take the drug tamoxifen for 10 years, instead of the recommended five, according to a British study. The study was a component of a larger international trial for which similar results were announced last year.Researchers estimated that, compared with taking no tamoxifen, 10 years of the drug reduces breast cancer death rates by a third in the first 10 years and by half after that. "Until now, there have been doubts whether...
Source: Guardian Unlimited Science - June 2, 2013 Category: Science Tags: The Guardian News Health Medical research Society Drugs UK news Breast cancer Science Source Type: news
New NICE guidelines for NHS fertility treatment
New standards set out for treating fertility problems dominate the health news.
The coverage is based on updated infertility guidance from the National Institute for Health and Clinical Excellence (NICE). While these guidelines are wide-ranging, the media’s coverage focuses largely on recommendations that:
NHS-funded IVF should now be offered up to the age of 42 (in certain circumstances) – the current IVF age limit is 39
couples having difficulty conceiving should be offered treatment after two years of regular unprotected intercourse, instead of the current three
same sex couples should be offere...
Source: NHS News Feed - February 20, 2013 Category: Consumer Health News Tags: QA articles Pregnancy/child Medical practice Source Type: news
NICE updates clinical guideline on fertility (CG156)
Source: NICE
Area: Evidence > Guidelines
NICE has updated its 2004 clinical guideline on fertility (CG 156) which offers evidence-based advice on the care and treatment of people with fertility problems.
Under the updated recommendations, NICE says that under certain criteria, women aged between 40 and 42 years should be offered one full cycle of IVF with or without intracytoplasmic sperm, if they have not conceived after two years of regular unprotected intercourse, or 12 cycles of artificial insemination where six or more are by intrauterine insemination. A full cycle is now defined as including one episo...
Source: NeLM - Guidelines - February 20, 2013 Category: UK Health Source Type: news
Exemestane, anastrozole conferred similar outcomes in breast cancer
Goss PE. J Clin Oncol. 2013;doi:10.1200/JCO.2012.44.7805. (Source: HemOncToday.com)
Source: HemOncToday.com - February 19, 2013 Category: Cancer & Oncology Source Type: news
Phase III study compares exemestane to anastrozole in the adjuvant treatment of early breast cancer
Source: Journal of Clinical Oncology
Area: News
According to the results of a Phase III study, the steroidal aromatase inhibitor (AI) exemestane is associated with similar breast cancer outcomes to the non-steroidal AI anastrozole when used in the adjuvant treatment of postmenopausal breast cancer.
The authors note that the standard adjuvant therapy for patients with hormone-dependent postmenopausal breast cancer involves 5 years of the non-steroidal AIs anastrozole and letrozole. There has however to date been no comparison of exemestane with a non-steroidal AI. Exemestane is an irreversible AI (so may suppres...
Source: NeLM - News - January 29, 2013 Category: Drugs & Pharmacology Source Type: news
